• Sichuan Kelun-Biotech reported interim Phase III OptiTROP-Lung05 results for sacituzumab tirumotecan with pembrolizumab in first-line PD-L1-positive NSCLC.
• Findings were published in The Lancet; the dataset was also selected for an oral presentation at the 2026 ASCO annual meeting.
• The combination delayed disease worsening versus pembrolizumab alone, supporting a potential shift toward ADC–immunotherapy regimens in this setting.
• Overall survival trended favorably; benefits were consistent across major patient subgroups.
• Safety was described as manageable, with no new signals versus known profiles of the individual drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605302000PR_NEWS_USPR_____CN71877) on May 31, 2026, and is solely responsible for the information contained therein.